Gastric Cancer Treatment Showed Potential in Pilot Study
A small clinical trial found that a targeted pre-operative approach may improve response rates for advanced stomach cancer.
Updated on Sept. 19, 2026 in Cancer
Researchers evaluated a pre-operative combination of transarterial infusion chemotherapy and embolization for patients with locally advanced gastric cancer. The pilot study found that 55% of participants achieved a pathological complete response.
Why it matters
This approach aims to shrink tumors before surgery, potentially reducing residual disease and lowering the risk of cancer recurrence. These findings represent a preliminary step in identifying new neoadjuvant strategies for managing advanced stomach cancer.
In a pilot study of 20 patients with locally advanced gastric cancer, the treatment achieved a 55% pathological complete response rate and a 70% major pathological response rate. These are preliminary results that require confirmation in larger, controlled clinical trials.
The players
NCT05396326
The official registry identifier for this clinical trial.
The details
The treatment combines transarterial infusion chemotherapy, which delivers high-dose drugs directly to the tumor site, with embolization to cut off the tumor's blood supply. By analyzing tumor feeding artery patterns and spatial transcriptomics, researchers aimed to better understand how these interventions impact postoperative survival. Lower residual tumor rates were linked to a reduced risk of recurrence in this group.
Timeline
September 19, 2026: Results published.
Health Landscape
This study contributes to the evolving field of neoadjuvant, or pre-operative, interventions for gastric cancer, moving beyond systemic chemotherapy alone. It follows an arc of research seeking to refine surgical outcomes by using targeted arterial delivery methods to address localized disease.
Patients currently navigating a diagnosis of locally advanced gastric cancer should discuss all available clinical trial options and neoadjuvant treatment paths with their oncology team. These findings are early, so they should be viewed as a signal for future research rather than a standard of care.
The takeaway
This pilot study demonstrates potential for reducing tumor burden before surgery for gastric cancer. Patients and families can track future findings from trials registered under NCT05396326 to monitor the development of these targeted delivery methods.
Further reading
For more on evolving treatment standards, visit our section on Cancer.
More information
View the study details on the clinical trial registration page.
Source note: This article includes information reported by Nature.
